Home » Stocks » MDXG

MiMedx Group, Inc. (MDXG)

Stock Price: $9.94 USD 0.22 (2.26%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $9.95 +0.01 (0.10%) May 7, 5:44 PM
Market Cap 1.11B
Revenue (ttm) 246.47M
Net Income (ttm) -88.36M
Shares Out 111.72M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $9.94
Previous Close $9.72
Change ($) 0.22
Change (%) 2.26%
Day's Open 9.81
Day's Range 9.70 - 9.95
Day's Volume 291,748
52-Week Range 5.32 - 12.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BATON ROUGE, La., May 4, 2021 /PRNewswire/ -- Prescience Point Capital Management ("Prescience Point"), a research-focused, catalyst-driven investment firm that is the beneficial owner of approximately ...

5 days ago - PRNewsWire

Questions Every Shareholder Should Ask Prescience Point

5 days ago - GlobeNewsWire

Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX's Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner

6 days ago - GlobeNewsWire

First Quarter Net Sales of $60.0 Million

1 week ago - GlobeNewsWire

Accomplished Regulatory Leader Joins MiMedx Management Team

1 week ago - GlobeNewsWire

MARIETTA, Ga., April 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, ...

2 weeks ago - GlobeNewsWire

Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option

2 weeks ago - GlobeNewsWire

No Shareholder Action Required at This Time

3 weeks ago - GlobeNewsWire

BATON ROUGE, La., April 16, 2021 /PRNewswire/ -- Prescience Point Capital Management, together with its affiliates ("Prescience Point"), a research-focused, catalyst-driven investment firm, announced to...

3 weeks ago - PRNewsWire

MARIETTA, Ga., March 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, tod...

1 month ago - GlobeNewsWire

Noted biopharmaceutical thought leader adds academic, research and industry expertise

2 months ago - GlobeNewsWire

Fourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million

2 months ago - GlobeNewsWire

MARIETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today anno...

2 months ago - GlobeNewsWire

MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today annou...

2 months ago - GlobeNewsWire

Persistent and sustained institutional buying in MiMedx should not be ignored as heavy hitters position themselves for key knee osteoarthritis data in 2021. Sales and revenue growth after two years of f...

4 months ago - Seeking Alpha

Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designation further...

4 months ago - Seeking Alpha

Experienced Healthcare Executive Will Expand Company's Visibility Within the Financial Community

5 months ago - GlobeNewsWire

MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today annou...

5 months ago - GlobeNewsWire

MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&D focus an...

5 months ago - Seeking Alpha

MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provi...

5 months ago - GlobeNewsWire

MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today annou...

5 months ago - GlobeNewsWire

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Third Quarter Net Sales of $64 . 3 M illion , Above Preliminary Range

6 months ago - GlobeNewsWire

MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today con...

6 months ago - GlobeNewsWire

Only Amniotic Product Covered Under Updated Commercial Policy

6 months ago - GlobeNewsWire

MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today ann...

6 months ago - GlobeNewsWire

MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today ann...

6 months ago - GlobeNewsWire

MARIETTA, Ga., Oct. 15, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, today ann...

6 months ago - GlobeNewsWire

Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally

7 months ago - GlobeNewsWire

Third Quarter 2020 Net Sales Expected to be Between $61 Million - $64 Million

7 months ago - GlobeNewsWire

Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders

7 months ago - GlobeNewsWire

New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade

7 months ago - GlobeNewsWire

MARIETTA, Ga., Aug. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics compan...

8 months ago - GlobeNewsWire

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities

8 months ago - GlobeNewsWire

Second Quarter Net Sales of $53.6 million

9 months ago - GlobeNewsWire

Strategic Leader with Proven Record of Delivering Growth and Business Transformation Strategic Leader with Proven Record of Delivering Growth and Business Transformation

9 months ago - GlobeNewsWire

MiMedx Fixes Cash Concerns With Relisting Right Around The Corner

9 months ago - Seeking Alpha

Company Now Caught Up in Financial Reporting

10 months ago - GlobeNewsWire

Annual Report on Form 10-K includes Audited Financial Results for 2019

10 months ago - GlobeNewsWire

Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management

10 months ago - GlobeNewsWire

March Flowers Could Bring MiMedx Showers Of Shareholder Returns

1 year ago - Seeking Alpha

MiMedx Group Inc. MDXG, +0.08% said Tuesday it has reached a settlement with the Securities and Exchange Commission to resolve a probe of its accounting practices.

1 year ago - Market Watch

10 Reasons To Buy MiMedx Stock Today

1 year ago - Seeking Alpha

A timetable of upcoming catalysts points to impressive upside potential by the end of 2019 and the beginning of 2020.

1 year ago - Seeking Alpha

August starts the watch for restatements of MiMedx's financials possibly right before the company's yet to be scheduled 2019 Annual Meeting.

1 year ago - Seeking Alpha

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

1 year ago - Seeking Alpha

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

1 year ago - Seeking Alpha

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

1 year ago - Seeking Alpha

Annual meeting on June 17th will be an inflection point for the company with former CEO Petit either embraced or shunned by MiMedx shareholders.

1 year ago - Seeking Alpha

About MDXG

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers,... [Read more...]

Industry
Medical Devices
Stock Exchange
NASDAQ
Ticker Symbol
MDXG
Full Company Profile

Financial Performance

In 2020, MiMedx Group's revenue was $248.23 million, a decrease of -17.05% compared to the previous year's $299.26 million. Losses were -$83.33 million, 225.8% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for MiMedx Group is 18.00, which is an increase of 81.09% from the latest price.

Price Target
$18.00
(81.09% upside)